Alectinib, a new 2nd generation lung cancer treatment, approved by FDA
The FDA ( Food and Drug Administration ) has approved a new second-generation lung cancer treatment that can help many patients in their battle against the disease. Lung cancer patients got another round of hope with the FDA's rapid progression of lung cancer drug approvals - this time for Alectinib ( Alecensa ) for patients with advanced ( metastatic ) ALK-positive non-small cell lung cancer ( NSCLC ) if their disease deteriorated after treatment with another therapy called Crizotinib ( Xalkori ). Patients who could not tolerate treatment with Crizotinib also qualify for use of Alectinib.
Lung cancer is the leading cause of cancer deaths around the world, responsible for claiming more lives than prostate, colon and breast cancer combined. Medications that target the individual characteristics of a patient's disease continue to create new options and hope for those with lung cancer.
For example, tumor cells in about 5% of lung cancer patients with NSCLC contain the ALK ( anaplastic lymphoma kinase ) genetic mutation.
In patients with metastatic cancer, the disease spreads to new part of the body. For ALK-positive NSCLC metastatic patients, the disease often spreads to the brain.
Many ALK-positive patients benefit from treatments called ALK inhibitors, such as Crizotinib which blocks the activity of the ALK protein and can prevent NSCLC cells from growing and spreading. Alectinib is an oral medication that performs similarly.
Patients can also develop resistance to ALK inhibitors such as Crizotinib, so Alectinib gives health professionals a new option to continue to extend their patients' life span.
The FDA previously approved Ceritinib ( Zykadia ) in the same treatment setting.
Alectinib is the fifth lung cancer treatment approved by the FDA since early October. The others include:
a) Necitumumab ( Portrazza ), an anti-EGFR antibody, in combination with standard chemotherapy to treat patients with advanced squamous NSCLC who did not previously received systemic therapy;
b) Two immunotherapy treatments: Nivolumab ( Opdivo ) and Pembrolizumab ( Keytruda );
c) Osimertinib ( Tagrisso ), a 3rd-generation EGFR tyrosine kinase inhibitor ( TKI ). ( Xagena )
Source: International Association for the Study of Lung Cancer ( IASLC ), 2015
Chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer: Cetuximab versus Panitumumab
The anti-EGFR monoclonal antibodies Panitumumab ( Vectibix ) and Cetuximab ( Erbitux ) are effective in patients with chemotherapy-refractory wild-type...
Bayer HealthCare has announced that the European Commission has approved Stivarga ( Regorafenib ) tablets for the treatment of adult...
Treatment-resistant colorectal cancer: MET inhibitors, alone or in combination with anti-EGFR therapies, offer novel therapeutic opportunities
A subset of colorectal cancers responds to anti-epidermal growth factor receptor ( anti-EGFR ) therapies, but develops resistance within months....
Select patients with advanced colorectal cancer and liver metastasis to undergo surgery: Cetuximab associated with chemotherapy extends median overall survival by 10 months compared with chemotherapy alone
Results from a clinical trial conducted in Shanghai, China, have indicated that adding Cetuximab ( Erbitux ) to standard chemotherapy...
Comparison of FOLFIRI plus Cetuximab versus FOLFIRI plus Bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer
In patients with KRAS, wild-type metastatic colorectal cancer ( mCRC ) a head to head comparison of anti-EGFR- and anti-VEGF-directed...
Bayer HealthCare has announced that the Food and Drug Administration ( FDA ) approved Stivarga ( Regorafenib ) tablets for...
European Researchers have found that metastatic colorectal cancer patients with a mutation in the BRAF gene do not respond to...
The anti-epidermal growth factor receptor ( anti-EGFR ) Cetuximab ( Erbitux ) has been proven to be efficient in metastatic...